Direction of development of medical treatment of infectious conjunctivities (literature review)


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Eye pathologies are serious diseases of modern man. Conjunctivitis make up about 35% of all eye diseases, they are the main clinical forms of eye infection - 66.7% of the total number of patients with inflammatory eye diseases. Conjunctivitis is an inflammatory disease of the conjunctiva, a thin transparent tissue that lines the inner surface of the eyelid and the visible part of the sclera, which has an infectious or other etiology. Infectious conjunctivitis is classified according to the course of the disease (acute or chronic) and etiological factor. By etiology are divided into the following types - bacterial, viral, chlamydial and fungal. The typical symptoms for bacterial conjunctivitis are copious discharge from the eyes; when dried, it gives a crust on the eyelashes and eyes. One of the problems arising from the use of various antimicrobial agents (biocides, antibiotics) is the ability of microorganisms consisting of representatives of one species or the association of microorganisms to form biofilms. Drugs that can prevent the development of biofilms or disrupt the structure are now of great interest all over the world. Recently, a number of guanidine-based polymeric preparations have become widely spread, the merits of which include a wide range of antimicrobial activity, both with respect to bacteria, yeast, viruses, and with respect to vegetative cells and fungal spores. One of the promising oligomeric guanidine derivatives is a branched oligohexamethylene guanidine hydrosuccinate. In conclusion, we can say that cationic polymers have a number of advantages compared with the traditionally used antimicrobial substances. Proven high efficacy against a number of pathogenic microorganisms, especially against yeast fungi of the genus Candida and Pseudomonas aeruginosa, and low toxicity makes it possible to use oligohexamethienguanidine hydrosuccinate as substances of pharmaceutical use, including for creating effective drugs for the treatment and prevention of infectious conjunctivitis.

Full Text

Restricted Access

About the authors

A. V Kovalenko

MIREA - Russian University of Technology

Student, Department of Biotechnology and Industrial Pharmacy

D. O Shatalov

MIREA - Russian University of Technology; Institute of Pharmaceutical Technologies JSC

Email: shat-05@mail.ru
Ph.D. (Pharm.), Associate Professor, Department of Biotechnology and Industrial Pharmacy; Deputy Executive Director

S. A Kedik

MIREA - Russian University of Technology; Institute of Pharmaceutical Technologies JSC

Dr.Sc. (Tech.), Professor, Head of the Department of Biotechnology and Industrial Pharmacy; Executive Director

A. I Gromakova

All-Russian Scientific Research Institute of Medicinal and Aromatic Plants

Dr.Sc. (Pharm.), Chief Researcher of the Scientific and Organizational Department

A. P Kaplun

MIREA - Russian University of Technology

Dr.Sc. (Chem.), Рrofessor, Department of Biotechnology and Industrial Pharmacy

I. S Ivanov

MIREA - Russian University of Technology

Post-graduate Student, Department of Biotechnology and Industrial Pharmacy

I. V Sterin

MIREA - Russian University of Technology

Student, Department of Biotechnology and Industrial Pharmacy

References

  1. Здравоохранение: Федеральная служба государственной статистики. [Офиц. сайт] URL: http://www.gks.ru/wps/ wcm/connect/rosstat_main/rosstat/ru/statistics/population/hea lthcare.
  2. Alfonso S.A., Fawley J.D., Lu X.A. Conjunctivitis // Primary Care: Clinics in Office Practice. 2015; 42(3):325-345.
  3. Чернакова Г.М., Клещева Е.А., Обрубов А.С., Овсянко А.А., Семенова Т.Б. Роль лабораторной диагностики при синдроме красного глаза // Альманах клинической медицины. 2015. № 36. С. 59-66.
  4. Житкова Е.Т., Зинченко А.А., Новиков О.О., Попов Н.Н. Разработка методики определения мирамистина и димедрола в новых пролонгированных глазных каплях для лечения бактериальных конъюнктивитов // Научные ведомости белгородского государственного университета. Сер. Медицина. Фармация. 2015. Т. 30. №10(207). С. 211-217.
  5. Жилякова Е.Т., Баскадова А.В., Новиков О.О., Комиссаров М.И., Фадеев А.Н. Разработка методики растворимости ацикловира // Научные ведомости белгородского государственного университета. Сер. Медицина. Фармация. 2013. № 25(168). С. 38-41.
  6. Воскресенская Л.К., Безкоровайная И.Н., Ряднова О.Ю., Максимук О.Ю. Эффективность применения противовирусных препаратов в комплексной терапии вирусных конъюнктивитов // Вюник проблем бюлогй i медицини. 2014. № 1(106). С. 76-79.
  7. Сакович В.Н. Аденовирусные поражения глаза: этиология, диагностика, клиника, лечение // Офтальмологш. 2015. № 2. С. 232-243.
  8. Ghebremedhin B. Human adenovirus: Viral pathogen with increasing importance // European Journal of Microbiology and Immunology. 2014; 4(1):26-33.
  9. Segal K.L., Lai E.C., Starr C.E. Management of acute conjunctivitis // Current Ophthalmology Reports. 2014; 2(3): 116-123.
  10. Jhanji V., Chan T.C.Y., Li E.Y.M., Agarwal K., Vajpayee R. Adenoviral keratoconjunctivitis // Survey of Ophthalmology. 2015; 60(5):435-443.
  11. Чекина А.Ю., Марченко Л.Н., Кудерко И.А., Вежбицкая Ю.Л., Акимова Л.В., Иванкова Л.А. Хламидийные конъюнктивиты: современная тактика лечения // Офтальмология Восточная Европа. 2012. № 1. С. 32-39.
  12. Andalibi S., Haidaraet M., Bor N., Levin M. An update on neonatal and pediatric conjunctivitis // Current Ophthalmology Reports. 2015; 3(3):158-169.
  13. de Vries H.J.C. Skin as an indicator for sexually transmitted infections // Clinics in dermatology. 2014; 32(2):196-208.
  14. Taylor H.R., Burton M.J., Haddad D., West S., Wright H. Trachoma // The Lancet. 2014; 384(9960):2142-2152.
  15. Giske C.G. Contemporary resistance trends and mechanisms for the old antibiotics colistin, temocillin, fosfomycin, mecil-linam and nitrofurantoin // Clinical Microbiology and Infection. 2015; 21(10):899-905.
  16. Голуб А.В. Бактериальные биопленкиновая цель терапии? // Клиническая микробиология и антимикробная химиотерапия. 2012; 14(1):23-29.
  17. Гостев В.В., Сидоренко С.В. Бактериальные биопленки и инфекции // Журнал инфектологии. 2014. Т. 2. №. 3. С. 4-15.
  18. Афиногенова А.Г., Даровская Е.Н. Микробные биопленки ран: состояние вопроса // Травматология и ортопедия России. 2011. №. 3.
  19. Jala J.F. Development of antimicrobial surfaces // The first European congresson microbial biofilms: Eurobiofilms. 2009; 2:51.
  20. Патент RU 2443684 С1, 2012, МПК C07C279/00, C08G73/00, A61L2/16. Разветвленные олигомеры на основе производного гуанидина и содержащее их дезинфицирующее средство / Кедик С.А., Седишев И.П., Панов А.В., ЖаворонокЕ.С., Ха Кам Ань.
  21. Афиногенов Г.Е., Панарин Е.Ф. Антимикробные полимеры. СПб: Гиппократ, 1993.
  22. Шаталов Д.О., Кедик СА., ЖаворонокЕ.С., Айдакова А.В., Иванов И.С., Евсеева А.С., Беляков С.В., Бирюлин С.И., Коваленко А.В., Михайленко Е.Н. Опыт и перспективы развития использования синтетических антимикробных веществ // Все материалы. Энциклопедический справочник. 2016. Вып. 8. С. 14-22.
  23. ГОСТ Р. 12.1. 007-76 Вредные вещества // Классификация и общие требования безопасности. М.: Издательство стандартов. 1976.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies